Paris-based Sensome has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the U.S. FDA for its Clotild Smart Guidewire System designed to improve the treatment of ischemic stroke patients.
Acute ischemic stroke, a leading cause of long-term disability, can be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices, which are guided from the groin over a wire to the blockage. To improve patient prognosis, the clot needs to be removed as quickly as possible. Today, without knowledge of the clot’s characteristics, the clot can only be removed on the first attempt in one out of three cases. Clotild Smart Guidewire System integrating Sensome’s AI-powered tissue sensor enables the guidewire to provide physicians with critical information on the clot.
The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. As part of this program, the FDA will provide Sensome with priority review and interactive communication on its path from device development to commercialization.
“This is a tremendous recognition by FDA that will boost our efforts to bringing Clotild to patients in the U.S.,” says Franz Bozsak, CEO and co-founder of Sensome, “The first-in-human clinical trial of Clotild is expected to start later this year outside the United States, which will take our device one step closer to improving care for ischemic stroke patients around the world.”
